[424B5] Dermata Therapeutics, Inc. Prospectus Supplement (Debt Securities)
Dermata Therapeutics (DRMA) filed a prospectus supplement for its at-the-market program, permitting sales of up to $1,792,315 of common stock through H.C. Wainwright & Co. under its effective S-3, subject to General Instruction I.B.6 limitations.
This cap reflects a public float of approximately $5,376,945, calculated on 910,575 non‑affiliate shares at $5.905 as of September 16, 2025. The amount does not include approximately $1,662,142 previously sold under earlier supplements. Any additional sales capacity will be addressed in a subsequent supplement.
DRMA’s common stock trades on Nasdaq under “DRMA”; the last reported sale price was $2.95 on November 6, 2025. The company is an emerging growth company and smaller reporting company.
- None.
- None.
Filed Pursuant to Rule 424(b)(5)
Registration No. 333-268383
PROSPECTUS SUPPLEMENT
(To Prospectus Supplements dated August 2, 2024, and June 7, 2024, to Prospectus dated November 25, 2022)
Up to $1,792,315
Common Stock
This prospectus supplement amends and supplements the information in the prospectus, dated November 25, 2022, filed as a part of our registration statement on Form S-3 (File No. 333-268383) (the “Registration Statement”), as supplemented by our prospectus supplements, dated June 7, 2024 and August 2, 2024 (collectively, the “Prior Prospectus”), relating to the offering, issuance and sale by us of our common stock, par value $0.0001 per share (“Common Stock”), from time to time that may be issued and sold under the at the market offering agreement (the “Sales Agreement”), dated June 7, 2024, by and between us and H.C. Wainwright & Co., LLC (“Wainwright”), as sales agent. This prospectus supplement should be read in conjunction with the Prior Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prior Prospectus. This prospectus supplement is not complete without, and may only be delivered or utilized in connection with, the Prior Prospectus, and any future amendments or supplements thereto.
We are filing this prospectus supplement to amend the Prior Prospectus to update the maximum amount of shares we are eligible to sell under our Registration Statement pursuant to General Instruction I.B.6 of Form S-3. As a result of these limitations and the current public float of our Common Stock, and in accordance with the terms of the Sales Agreement, we may offer and sell shares of our Common Stock having an aggregate offering price of up to $1,792,315 from time to time through Wainwright, which does not include the shares of Common Stock having an aggregate sales price of approximately $1,662,142 that were sold pursuant to the Prior Prospectus to date. In the event that we may sell additional amounts under the Sales Agreement and in accordance with General Instruction I.B.6, we will file another prospectus supplement prior to making such additional sales.
As of the date of this prospectus supplement, the aggregate market value of our outstanding Common Stock held by non-affiliates (the “public float”), was approximately $5,376,945, which was calculated based on 910,575 shares of our outstanding Common Stock held by non-affiliates at a price of $5.905 per share, the closing price of our Common Stock on the Nasdaq Capital Market on September 16, 2025. During the twelve (12) calendar months prior to and including the date of this prospectus supplement, we have not sold any securities pursuant to General Instruction I.B.6 of Form S-3. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities in a public primary offering with a value exceeding one-third of our public float in any 12 calendar-month period so long as our public float remains below $75.0 million. In the event that we may sell additional amounts under the Sales Agreement, we will file another prospectus supplement prior to making such additional sales.
We are an “emerging growth company” as defined in Section 2(a) of the Securities Act and a smaller reporting company as defined under Rule 405 of the Securities Act, and as such, we have elected to comply with certain reduced public company reporting requirements. See ‘‘Prospectus Supplement Summary— Implications of Being an Emerging Growth Company and a Smaller Reporting Company” on page S-4 of the Prior Prospectus.
Our Common Stock is listed on the Nasdaq Capital Market under the symbol “DRMA.” On November 6, 2025, the last reported sale price of our Common Stock on the Nasdaq Capital Market was $2.95 per share.
Investing in the offered securities involves a high degree of risk. Before buying any shares, you should read the discussion of material risks of investing in our Common Stock in “Risk Factors” beginning on page S-6 of the Prior Prospectus, and in the risks discussed under similar headings in the documents incorporated by reference in this prospectus supplement and the Prior Prospectus, as they may be amended, updated or modified periodically in our reports filed with the Securities and Exchange Commission.
NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ADEQUACY OR ACCURACY OF THIS PROSPECTUS SUPPLEMENT AND THE ACCOMPANYING PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
H.C. Wainwright & Co.
The date of this prospectus supplement is November 7, 2025
FAQ
What does Dermata (DRMA) register in this 424B5 supplement?
What limits apply to DRMA’s ATM under Form S-3 I.B.6?
What is DRMA’s public float used to set the cap?
How much had DRMA already sold under prior supplements?
Who is the sales agent for DRMA’s ATM program?
What was DRMA’s latest reported market price?
What is DRMA’s reporting status?
